 Home > Active Ingredient News > Antitumor Therapy > NEJM: The overall survival benefit of Tebentafusp for metastatic uveal melanoma

NEJM: The overall survival benefit of Tebentafusp for metastatic uveal melanoma

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

metastatic tumor

primary treatment wastewater

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Uveal melanoma is a disease different from skin melanoma.

Tebentafusp is a bispecific protein that is formed by the fusion of an affinity-enhanced T cell receptor and an anti-CD3 effector, which can redirect T cells to target glycoprotein 100-positive cells

This study is an open-label phase 3 clinical trial that recruited HLA-A*02:01-positive patients with metastatic uveal melanoma who had not been treated before.

Overall survival of the intention-to-treat population

A total of 378 patients were randomly divided into two groups: 252 in the Tebentafusp group and 126 in the control group

The 1-year overall survival rates of the Tebentafusp group and the control group were 73% and 59%, respectively.

Progression-free survival in the intention-to-treat population

The most common treatment-related adverse events in the Tebentafusp group were cytokine-mediated events (due to T cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including skin rash (83%), fever (76%) and itching (69%)

Changes in the incidence of treatment-related adverse events

All in all, compared with the control treatment, Tebentafusp treatment prolonged the overall survival of previously untreated patients with metastatic uveal melanoma

Compared with the control treatment, Tebentafusp treatment prolonged the overall survival of previously untreated patients with metastatic uveal melanoma

Original source:

Paul Nathan, et al.

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.